Cytos says drug meets main target in study

* Says cut allergy symptoms, improved quality of life

* Swiss group has cut jobs after another product failed

ZURICH, July 31 (Reuters) - A treatment from Swiss biotech company Cytos (CYTN.S) for allergic rhinoconjunctivitis met its main target in a mid-stage trial, the group said on Friday.

Patients taking CYT003-QbG10 in the Phase IIb study had significantly lower allergy symptoms and reported a better quality of life than those taking placebo, Cytos said in a statement.

The trial included nearly 300 patients and Cytos said the product should attract partnering interest from pharmaceutical companies once further clinical results in allergic asthma are reported in early 2010.

The Zurich-based group focuses on so-called immunodrugs, aimed at treating chronic diseases and addictions through vaccination, but has said it would cut about 40 percent of its workforce after a high blood pressure vaccine failed in a mid-stage study. [ID:nLH230277] (Reporting by Sam Cage; Editing by Greg Mahlich)